Transcription profiling of rat model of pulmonary hypertension reveals Multi- Kinase Inhibitor Modulates Pulmonary Hypertension - Rodent Model 2

ABSTRACT: Pulmonary hypertension (PH) and cancer pathophysiology share common signal transduction pathways leading to abnormal endothelial and smooth muscle cell interactions and angioproliferative vasculopathy. Sorafenib (Sor) a drug in clinical trials for cancer treatment, is an inhibitor of multiple kinases important in angiogenesis (Raf-1 kinase, VEGFR-2, VEGFR-3, PDGFR-). In this study, we assessed the efficacy of Sor as a potential therapy for PH, and hypothesized that Sor prevents the development of both a conventional and an augmented rodent model of PH. We performed studies in Dahl Salt-Sensitive rats (SS) exposed to hypoxia alone and in combination with the VEGFR-2 inhibitor, SU5416, known to induce a well-characterized augmented PH phenotype. Rats were, thus, divided into 5 groups

ORGANISM(S): Rattus norvegicus

SUBMITTER: Ankit Desai 

PROVIDER: E-GEOD-8132 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress